Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

@article{Sartor2013PainAF,
  title={Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.},
  author={Alton Oliver Sartor and Oyvind Sverre Bruland and Fang Fang and A K Aksnes and Christopher C. Parker},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 6_suppl},
  pages={19}
}
19 Background: Bone metastases (mets), present in >90% of patients (pts) with CRPC, may cause severe pain. In a phase II dose-response study with Ra-223 treatment, pain response (pain reduction and stable analgesic consumption) was seen in up to 71% of CRPC pts with painful bone mets (Nilsson 2012). In the phase III ALSYMPCA study, which included 921 CRPC pts with bone mets randomized 2:1 to receive 6 injections of Ra-223 (50 kBq/kg IV) q4wk or matching placebo (Ra-223, n=614; placebo, n=307… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

[Review on quality of life in CRPC patients].

Aktuelle Urologie • 2017
View 3 Excerpts

Radium-223 dichloride in clinical practice: a review

European Journal of Nuclear Medicine and Molecular Imaging • 2016
View 1 Excerpt

Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting • 2014

Similar Papers

Loading similar papers…